SCHEMBL22426232

SCHEMBL22426232

CCCNC1CC(=O)N(Cc2ccccc2)C1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.64
KMT2A Q03164 4/20 0.62
MEN1 O00255 3/20 0.62
ALDH1A1 P00352 13/20 0.61
POLB P06746 2/20 0.61
GAA P10253 5/20 0.56
TSHR P16473 3/20 0.56
HSD17B10 Q99714 2/20 0.56
MAPT P10636 3/20 0.55
HPGD P15428 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
STAT6 P42226 1/20 0.51
ALOX15 P16050 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51
ALOX12 P18054 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22426231 1.00 SMN1; SMN2 (0.64) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL6837461 0.92 SMN1; SMN2 (0.61) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL22426269 0.90 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL22426270 0.90 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL22426242 0.87 KMT2A (0.78) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL22426241 0.87 KMT2A (0.78) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL6214766 0.87 SMN1; SMN2 (0.66) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL9634928 0.84 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL22426264 0.84 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1ALDH1A1POLB
SCHEMBL22426257 0.80 ALDH1A1 (0.71) SMN1; SMN2KMT2AMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840514-B2 Catalysts and methods for enantioselective conjugate addition of amines to unsaturated electrophiles NORTHWESTERN UNIVERSITY (US) 2023-12-12 US disclosed
US-20210002221-A1 CATALYSTS AND METHODS FOR ENANTIOSELECIVE CONJUGATE ADDITION OF AMINES TO UNSATURATED ELECTROPHILES NORTHWESTERN UNIVERSITY 2021-01-07 US disclosed
US-10781172-B2 Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles NORTHWESTERN UNIVERSITY (US) 2020-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840514-B2 Catalysts and methods for enantioselective conjugate addition of amines to unsaturated electrophiles AADAC, COASY, PAICS SMN1; SMN2 934/4885KMT2A 1436/4885MEN1 1915/4885
US-10781172-B2 Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles AADAC, COASY, PAICS SMN1; SMN2 999/4885KMT2A 1587/4885MEN1 2044/4885
US-20210002221-A1 CATALYSTS AND METHODS FOR ENANTIOSELECIVE CONJUGATE ADDITION OF AMINES TO UNSATURATED ELECTROPHILES COASY, AADAC, AOC1 SMN1; SMN2 1076/4885KMT2A 1916/4885MEN1 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.